Appendix B Comments Inactivated, Adj. Inactivated, Adj. Recombinant, Inactivated, Adj. Inactivated, Inactivated, Adj. Adj. Inactivated, conjugate) (Meningococcal Inactivated (Tetanus toxoid toxoid Inactivated (Tetanus conjugate) Recombinant, Adj. Recombinant, Adj. Recombinant, Inactivated, Adj. Inactivated, Use Adj.: Inactivated, when pertussis is contraindicated toxoid Inactivated (Tetanus conjugate) Live: Approved for military for Approved Live: not approved populations; women pregnant for from filtrate Cell-free Adj. strain, avirulent Recombinant, Adj. Recombinant, Live Attenuated Live Adj. Inactivated,

Approved Ages Approved Pediatric: Pediatric: years; 12 months-18 ≥19 years Adult: Pediatric: years Birth-19 ≥20 years Adult: 12 months-18 years; years; 12 months-18 ≥19 years Adult: 2-71 months Pediatric: 6 weeks- 4 years 6 weeks- ≥18 years ≥50 years 6 weeks-6 years 6 weeks-6 years 6 weeks-6 years 2 months-5 17-50 years 18-65 years Birth-19 years years Birth-19 ≥20 years Adult: 18-64 years years 6 weeks-6 Pediatric: Series Doses in Routine 2 3 3 2 4 2 2 5 5 4 1 3 1 5 3 Route IM IM IM IM IM IM IM IM IM IM IM Oral (2 Tablets) IM Oral (Liquid) Oral IM Manufacturer Merck Merck GlaxoSmithKline Merck GlaxoSmithKline GlaxoSmithKline Dynavax Technologies GlaxoSmithKline GlaxoSmithKline Sanofi Sanofi Teva Pharmaceutical Industries Ltd. Emergent BioSolutions Emergent Emergent BioSolutions Sanofi Abbreviation HepB HepA HepB Hib (PRP-OMP) HepA Hib (PRP-T) HepB RZV DTaP DT Hib (PRP-T) N/A AVA N/A DTaP † Trade Name Trade Recombivax HB® Recombivax Vaqta® Engerix-B™ PedvaxHIB® Havrix™ Hiberix™ Heplisav-B® Shingrix™ Infanrix™ N/A (Generic) ActHIB® Adenovirus 7 Type 4 & Type BioThrax® Vaxchora™ Daptacel®

B Vaccine Hepatitis B Hepatitis Hepatitis A Hepatitis Herpes Zoster Herpes Zoster (Shingles) DT Haemophilus influenzae type b (Hib) Adenovirus Anthrax Cholera DTaP United States Vaccine Names United States Vaccine United States Vaccines

Appendix B-3 Appendix B

Comments conjugate) 197 Recombinant, Adj. Recombinant, recommends ACIP 9-26 years Inactivated Adj. Inactivated, Adj. Inactivated, Inactivated Egg-Free Recombinant, Egg-free Cell-culture, Inactivated Attenuated Live Inactivated Inactivated Adj. Inactivated, Attenuated Live Inactivated (Polysaccharide toxoid diphtheria conjugate) Inactivated (Polysaccharide conjugate) toxoid tetanus Inactivated (Polysaccharide CRM Adj. Recombinant, Adj. Recombinant, Approved Ages Approved 9-45 years ≥6 months ≥65 years ≥65 years ≥6 months ≥18 years ≥4 years ≥6 months 2-49 years ≥6 months ≥65 years ≥2 months ≥12 months years 9 months-55 ≥2 years years 2 months-55 10-25 years 10-25 years Series Doses in Routine 2 or 3 1 or 2 1 1 1 or 2 1 1 or 2 1 or 2 1 or 2 1 or 2 1 2 2 2 2 2 2 or 3 2 Route IM IM IM IM IM IM IM IM Intranasal IM IM IM SC IM IM IM IM IM Manufacturer Merck Seqirus Seqirus Seqirus GlaxoSmithKline Sanofi Seqirus GlaxoSmithKline AstraZeneca Sanofi Sanofi Valneva Merck Sanofi Sanofi GlaxoSmithKline Pfizer GlaxoSmithKline Abbreviation 9vHPV IIV4 IIV3 IIV4 IIV4 RIV4 ccIIV4 IIV4 LAIV4 IIV4 HD-IIV4 JE MMR MenACWY-D MenACWY-TT MenACWY-CRM MenB-FHbp MenB-4C Trade Name Trade Gardasil® 9 Gardasil® Afluria Quadrivalent® Fluad® Fluad® Quadrivalent Fluarix™ Quadrivalent Flublok® Quadrivalent Flucelvax® Quadrivalent FluLaval™ Quadrivalent FluMist® Quadrivalent Fluzone® Quadrivalent Fluzone® High-Dose Quadrivalent Ixiaro® M-M-R® II Menactra® Menquadfi™ Menveo™ Trumenba® Bexsero™

B Vaccine Human Papillomavirus (HPV) Influenza* Japanese encephalitis , , Meningococcal W, A, C, (serogroups and Y) Meningococcal B) (serogroup

Appendix B-4 Appendix B

197 Comments Live Attenuated Live Inactivated, Adj. (CRM Adj. Inactivated, Live, Monovalent Live, Adj. Inactivated, Adj. Inactivated, Inactivated Polysaccharide Inactivated Polysaccharide Inactivated Pentavalent Live, Adj. Inactivated, Adj. Inactivated, Attenuated Live Attenuated Live Non-replicating Live, Attenuated Live conjugate) Inactivated Inactivated

Approved Ages Approved ≥6 years Pediatric: ≥6 weeks Pediatric: >65 years Adult: 6-24 weeks ≥7 years 10-64 years ≥2 years ≥2 years All ages 6-32 weeks ≥7 years ≥10 years ≥12 months All ages ≥18 years ≥9 months ≥6 weeks All ages

Series (post-exposure) Doses in Routine 4 2 4 (pediatric) 4 (pediatric) 1 (adult) 2 1 (Every 10 years) 1 1 2-3 (pre-exposure) 4 1 3 1 (Every 10 years) 1 1 2 1 4 2-3 (pre-exposure) 4 (post-exposure) Route Oral (Capsules) SC IM Oral (Liquid) Oral IM IM IM IM IM or SC Oral (Liquid) Oral IM IM Percutaneous SC SC IM or SC IM Manufacturer Emergent Emergent BioSolutions Merck Pfizer GlaxoSmithKline Sanofi Sanofi Sanofi Bavarian Nordic Bavarian Merck Massachusetts Labs Biological Merck GlaxoSmithKline Emergent BioSolutions Nordic Bavarian Sanofi Sanofi Sanofi Abbreviation N/A VAR PCV13 RV1 Tdap Td N/A N/A PPSV23 Td RV5 Tdap — — YF IPV N/A TM Trade Name Trade TdVax Vivotif® Varivax® Prevnar 13® Prevnar Rotarix™ Adacel® Tenivac® Vi® Typhim RabAvert® Pneumovax® 23 Pneumovax® RotaTeq® Boostrix™ ACAM2000® JYNNEOS® YF-Vax® Ipol® Imovax®

B Vaccine Varicella Tetanus, Tetanus, (reduced) Diphtheria Typhoid Pneumococcal Rotavirus (reduced) Tetanus, Diphtheria, Pertussis (reduced) () and Smallpox Monkeypox Fever Yellow Polio Rabies of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP. the ACIP. to and liaison organizations members, Book), ACIP Diseases (the Pink Vaccine-Preventable of Reportof the Morbidity of Epidemiology and Prevention and MortalityWeekly (MMWR), the editor of Book, published in the MMWR, Pink and the American Academy Notes and Policy Recommendations used in ACIP references vaccine to approach a uniform provide to intended are abbreviations These are products in which the active components (-) indicates a hyphen vaccines, In descriptions of combination and adults. adolescents, children, schedules for immunization Red Book, and in the U.S. Pediatrics by the user. must be mixed components products in which activeby the manufacturer; form a slash ( / ) indicates (combined) supplied in their final and not product, that number of doses for the routine represents this column vaccines, some combination doses not part or booster For schedules, of an initial series. catch-up schedules, alternative factors, and IPV series.) only 1 dose of multi-dose be used for DTaP may Kinrix or Quadracel example, (For the components. series for number of doses in a complete the total necessarily https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html May be limited in supply as manufacturer has temporarily stopped production stopped in supply as manufacturer has temporarily be limited May The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP) Work Groups, the editor the editor Work Groups, (ACIP) Practices Advisory on Committee Immunization Prevention, and Control for Disease Centers staff of the by jointly standardized 3) were on this table (Column abbreviations The conditions or other high-risk with health patients reflect for schedules It does not necessarily ages. recommended at the patient to a healthy 6) reflects doses administered (Column “Doses in a Routine Series” an adjuvant. contains the vaccine that indicates column “Comments” in the “Adj.” the 7th birthday]). [to 6 years through means 6 weeks years” “6 weeks-6 (i.e., “through” means in an age range A hyphen on influenza, see: recommendations For the most current 2020-2021 northernformulations. in this table are vaccines *All influenza hemisphere †

Appendix B-5 Appendix B Comments Inactivated, Adj.: Approved as Approved Adj.: Inactivated, and 4th IPV. 5th DTaP as Approved Adj.: Inactivated, and 4th IPV. 5th DTaP for Approved Adj.: Inactivated, doses. 2, 4, 6 month Approved Adj.: 4 Inactivated, doses. 2, 4, 6, 15-18 month for for Approved Adj.: Inactivated, doses. 2, 4, 6 month Adj. Inactivated/Recombinant, HepB HepA + Adult Pediatric Attenuated Live

Ages Approved Approved 4-6 years 4-6 years years 6 weeks-6 years 6 weeks-4 years 6 weeks-4 ≥18 years 12 months- 12 years

Series Routine Doses in 1 1 3 4 3 3 2 Route IM IM IM IM IM IM SC Manufacturer GlaxoSmithKline Sanofi GlaxoSmithKline Sanofi Sanofi GlaxoSmithKline Merck Abbreviation DTaP-IPV DTaP-IPV DTaP-HepB-IPV DTaP-IPV/Hib DTaP-IPV-Hib-HepB HepA-HepB MMRV Trade Trade Name Kinrix™ Quadracel® Pediarix™ Pentacel® Vaxelis™ Twinrix™ ProQuad®

B Vaccine DTaP, Polio DTaP, B, hepatitis DTaP, Polio Polio, DTaP, Haemophilus influenzae type b Polio, DTaP, Haemophilus influenzae type b, B hepatitis A, Hepatitis B Hepatitis Mumps, Measles, Rubella, Varicella of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP. the ACIP. to and liaison organizations members, Book), ACIP Diseases (the Pink Vaccine-Preventable of Reportof the Morbidity of Epidemiology and Prevention and MortalityWeekly (MMWR), the editor of Book, published in the MMWR, Pink and the American Academy Notes and Policy Recommendations used in ACIP references vaccine to approach a uniform provide to intended are abbreviations These are products in which the active components (-) indicates a hyphen vaccines, In descriptions of combination and adults. adolescents, children, schedules for immunization Red Book, and in the U.S. Pediatrics by the user. must be mixed components products in which activeby the manufacturer; form a slash ( / ) indicates (combined) supplied in their final and not product, that number of doses for the routine represents this column vaccines, some combination doses not part or booster For schedules, of an initial series. catch-up schedules, alternative factors, and IPV series.) only 1 dose of multi-dose be used for DTaP may Kinrix or Quadracel example, (For the components. series for number of doses in a complete the total necessarily The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP) Work Groups, the editor the editor Work Groups, (ACIP) Practices Advisory on Committee Immunization Prevention, and Control for Disease Centers staff of the by jointly standardized 3) were on this table (Column abbreviations The conditions or other high-risk with health patients reflect for schedules It does not necessarily ages. recommended at the patient to a healthy 6) reflects doses administered (Column “Doses in a Routine Series” an adjuvant. contains the vaccine that indicates column “Comments” in the “Adj.” the 7th birthday]). [to 6 years through means 6 weeks years” “6 weeks-6 (i.e., “through” means in an age range A hyphen 2021 February United States Combination Vaccines

Appendix B-6